Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rallybio Corporaton (NQ: RLYB )

1.020 UNCHANGED
Streaming Delayed Price Updated: 2:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 51,037
Open 1.020
Bid (Size) 1.010 (9)
Ask (Size) 1.020 (4)
Prev. Close 1.020
Today's Range 0.9990 - 1.080
52wk Range 0.9616 - 4.503
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
From Rallybio Corporation
Via Business Wire
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire

Performance

YTD
-57.50%
-57.50%
1 Month
-12.82%
-12.82%
3 Month
-26.62%
-26.62%
6 Month
-46.32%
-46.32%
1 Year
-75.71%
-75.71%

More News

Read More
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024
Via InvestorPlace
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
From Rallybio Corporation
Via Business Wire
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
From Rallybio Corporation
Via Business Wire
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
Rallybio to Present at Upcoming Investor Conferences
From Rallybio Corporation
Via Business Wire
RLYB Stock Earnings: Rallybio Misses EPS for Q2 2024
Via InvestorPlace
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
From Rallybio Corporation
Via Business Wire
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
3 Sorry Biotech Stocks to Sell in May While You Still Can
Via InvestorPlace
3 Biotech Stocks to Sell in May Before They Crash & Burn
Via InvestorPlace
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
From Rallybio Corporation
Via Business Wire
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Nasdaq Jumps 250 Points; Crude Oil Down 1%
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.